Governments have decided they will pay any price in the fight against COVID-19 while the pharmaceutical sector is already grappling with supply. Nobody should expect the PBS in 2021, 2022 or beyond to look like it does in 2020 - and that is before you even consider the long-term budgetary impact of the shock about to hit the economy.
This is just the start of a challenge that will almost certainly leave a permanent 'scar'
March 21, 2020 Latest NewsComment
Latest Video
New Stories
-
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News


